title: Resveratrol in cholesterol metabolism and atherosclerosis.
abstract: Resveratrol, a natural polyphenol produced by plants in response to environmental stress, has received great attention during the past few years due to its beneficial roles in longevity and glucose homeostasis. Resveratrol has been found to display antioxidant, anti-inflammatory, antifibrotic, and cardioprotective properties. Resveratrol reduces platelet aggregation, induces vasorelaxation, limits endothelial activation, and modulates lipid and lipoprotein metabolism. Although the mechanisms of action of resveratrol have not been completely defined, there is evidence that some of the effects of resveratrol may be mediated via activation of sirtuin 1 and AMP-activated protein kinase and through inhibition of the pleiotropic transcription factor nuclear factor κB. Pathways proposed to underlie resveratrol-mediated cardioprotection include reduction of oxidative stress and activation of endothelial nitric oxide synthase. Adenosinergic mechanisms may play a role in its atheroprotective activity. The ability of the nutraceutical resveratrol to positively influence the future treatment of cardiovascular disease is discussed.
authors.affiliation: Winthrop Research Institute and Department of Medicine, Winthrop-University Hospital, Mineola, New York 11501, USA.
authors.forename: Iryna
authors.initials: I
authors.lastname: Voloshyna
authors.forename: Syed M
authors.initials: SM
authors.lastname: Hussaini
authors.forename: Allison B
authors.initials: AB
authors.lastname: Reiss
mesh_terms: D043924:Angiogenesis Modulating Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D000818:Animals; D000975:Antioxidants / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000097:blood / Q000378:metabolism / Q000517:prevention & control*; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood / Q000378:metabolism*; D019587:Dietary Supplements / Q000009:adverse effects; D006801:Humans; D000077185:Resveratrol; D013267:Stilbenes / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D043924:Angiogenesis Modulating Agents; D000975:Antioxidants; D002316:Cardiotonic Agents; D013267:Stilbenes; D014665:Vasodilator Agents; D002784:Cholesterol; D000077185:Resveratrol